Hannover

• Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicl … Recruiting
  2024-514364-54-00 5 2021-10-18 moderate to severely inflamed candidiasis of the skin
• FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo … Recruiting
  2024-518077-34-00 5 2020-09-30 locally advanced rectal cancer
• A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune … Recruiting
  2024-514494-21-00 4 2020-05-13 autoimmune encephalitis
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 5 2019-12-05 Stage IV childhood renal tumour with pulmonary +/- non-pulmonary metas
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513282-39-00 5 2025-05-28 Hidradenitis Suppurativa (HS)
• Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Long-Term Extension Study (STOP-HS LTE) Ended recruitment
  2023-507204-31-00 5 2024-07-26 Hidradenitis Suppurativa
• A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended recruitment
  2023-504541-31-00 5 2024-03-06 Myelodysplastic syndrome
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult … Ended recruitment
  2022-500861-29-00 5 2023-01-12 Relapsed or Refractory Multiple Myeloma (RRMM)
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p … Ended recruitment
  2024-516438-36-00 4 2022-09-13 Patients with very low, low or intermediate risk myelodysplastic syndr
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended recruitment
  2024-511929-60-00 4 2021-01-28 Waldenström’s Macroglobulinemia
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty … Ended recruitment
  2024-513947-94-00 4 2020-03-30 locally advanced (stage III) and not suitable for curative treatment,
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended recruitment
  2024-514945-12-00 10 2018-09-03 locally advanced resectable adenocarcinoma of the oesophagogastric jun
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1) Ended
  2024-515864-30-00 4 2025-03-12 Heterozygous familial hypercholesterolemia

Showing 25–48 of 61 trials